A Phase 3 Placebo-controlled Study to Evaluate the Efficacy and Safety of Intra-articular Administration of Resiniferatoxin Versus Placebo for the Treatment of Moderate to Severe Pain Due to Osteoarthritis of the Knee
Latest Information Update: 12 Nov 2021
At a glance
- Drugs Resiniferatoxin (Primary)
- Indications Pain
- Focus Registrational; Therapeutic Use
- Sponsors Sorrento Therapeutics
Most Recent Events
- 02 Nov 2021 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 29 Sep 2020 Planned End Date changed from 1 Feb 2023 to 1 Mar 2023.
- 29 Sep 2020 Planned primary completion date changed from 1 Feb 2022 to 1 Mar 2023.